Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.

NCT00902525 is registered in ClinicalTrials.gov with Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie as lead sponsor.

NCT NCT00902525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00902525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.
Lead sponsor
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2008
Completion date
September 30, 2011
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma